Weight Loss

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month

The Danish drugmaker's arch-rival Eli Lilly & Co. has introduced another shot - Zepbound, also known as Mounjaro - that so far has shown even more weight loss than Wegovy

Half of the states without coverage said they are considering adding them or evaluating their coverage, it said

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been resolved

The Food and Drug Administration has listed an ongoing shortage of Lilly's medicines since December 2022

Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance

Indi had the third largest number of people with obesity as of 2022, behind China and the US, according to a study in The Lancet, with numbers surging as junk food consumption becomes more commonplace

As they've grown in popularity, we've also heard more about the potential side effects - from common gastrointestinal discomforts, to more serious mental health concerns

The American pharmaceutical giant is set to introduce its obesity drug, a competitor to Nova Nordisk's Ozempic, in India as early as next year

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026

State and local governments across the US are grappling with a growing problem: Expensive drugs to treat diabetes and obesity are threatening to drain their health-care budgets

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, US regulators announced on Wednesday. The US Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body weight, or 60 pounds (27 kilograms), in a recent study. Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic. The FDA approved Lilly's drug for people who are considered obese, with a body mass index of 30 or higher, or those who are overweight with a related health condition, like high blood pressure, high cholesterol or diabetes. The drug should be paired with a healthy diet and regular exercise, the FDA said. In the US, at least 100 million adults and about 15 million children are considered obese. The drug tirzepatide in Zepbound and Mounjaro and semaglutide in Wegovy and Ozempic work by mimicking hormones that kick

There could be a more than $100 billion global market for such medicines, with sales climbing quickly through the end of the decade

Researchers showed that when energy-restricted diets were supplemented with Californian almonds or carbohydrate-rich snacks, both diets successfully lowered body weight by roughly 7kg

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented

Artificial sweeteners were also linked with higher risk of developing type 2 diabetes and cardiovascular disease, as well as of dying, according to the WHO

The drug maker claimed that the new drug Tirzepatide has enabled people with obesity or who are overweight to lose about 22.5 per cent of their body weight

North Korean leader's weight has long been tracked by spy agencies for clues about the stability of his regime.